Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Jan;65(1):45–50. doi: 10.1038/bjc.1992.9

Ras p21 in breast tissue: associations with pathology and cellular localisation.

J J Going 1, T J Anderson 1, A H Wyllie 1
PMCID: PMC1977366  PMID: 1733441

Abstract

Immunocytochemistry with monoclonal antibody Y13-259 demonstrated p21 ras in paraffin sections of breast tissue from 171 women: 85 with invasive breast carcinoma, 14 with non-invasive carcinoma and 72 with benign changes only. Many different tissue elements contributed to ras expression. Semiquantitative assessment showed that intensity of immunostaining in the normal epithelium of large ducts, small extralobular ducts and terminal duct lobular units (TDLU) was usually exceeded by that of myoepithelial cells. Vascular smooth muscle and apocrine epithelium also stained strongly, but the flat epithelial cells lining cysts did not express detectable p21 ras. There was a progressive increase from normal epithelium through epithelial hyperplasia of usual type and atypical hyperplasia to carcinoma in situ, without further increase in invasive carcinoma. Expression in carcinomas was inversely related to oestrogen receptor content but independent of the prognosis-associated variables of size, histological type, vascular invasion or lymph node metastasis.

Full text

PDF
45

Images in this article

47Figure 1
on p.47

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson T. J. Genesis and source of breast cancer. Br Med Bull. 1991 Apr;47(2):305–318. doi: 10.1093/oxfordjournals.bmb.a072472. [DOI] [PubMed] [Google Scholar]
  2. Bar-Sagi D., Gomperts B. D. Stimulation of exocytotic degranulation by microinjection of the ras oncogene protein into rat mast cells. Oncogene. 1988 Oct;3(4):463–469. [PubMed] [Google Scholar]
  3. Benz C. C., Scott G. K., Santos G. F., Smith H. S. Expression of c-myc, c-Ha-ras1, and c-erbB-2 proto-oncogenes in normal and malignant human breast epithelial cells. J Natl Cancer Inst. 1989 Nov 15;81(22):1704–1709. doi: 10.1093/jnci/81.22.1704. [DOI] [PubMed] [Google Scholar]
  4. Birchmeier C., Broek D., Wigler M. ras proteins can induce meiosis in Xenopus oocytes. Cell. 1985 Dec;43(3 Pt 2):615–621. doi: 10.1016/0092-8674(85)90233-8. [DOI] [PubMed] [Google Scholar]
  5. Bizub D., Heimer E. P., Felix A., Chizzonite R., Wood A., Skalka A. M., Slater D., Aldrich T. H., Furth M. E. Antisera to the variable region of ras oncogene proteins, and specific detection of H-ras expression in an experimental model of chemical carcinogenesis. Oncogene. 1987 May;1(2):131–142. [PubMed] [Google Scholar]
  6. Bollag G., McCormick F. Differential regulation of rasGAP and neurofibromatosis gene product activities. Nature. 1991 Jun 13;351(6327):576–579. doi: 10.1038/351576a0. [DOI] [PubMed] [Google Scholar]
  7. Bourne H. R., Sanders D. A., McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature. 1991 Jan 10;349(6305):117–127. doi: 10.1038/349117a0. [DOI] [PubMed] [Google Scholar]
  8. Buehring G. C., Jensen H. M. Lack of toxicity of methylene blue chloride to supravitally stained human mammary tissues. Cancer Res. 1983 Dec;43(12 Pt 1):6039–6044. [PubMed] [Google Scholar]
  9. Candlish W., Kerr I. B., Simpson H. W. Immunocytochemical demonstration and significance of p21 ras family oncogene product in benign and malignant breast disease. J Pathol. 1986 Nov;150(3):163–167. doi: 10.1002/path.1711500303. [DOI] [PubMed] [Google Scholar]
  10. Chardin P., Tavitian A. The ral gene: a new ras related gene isolated by the use of a synthetic probe. EMBO J. 1986 Sep;5(9):2203–2208. doi: 10.1002/j.1460-2075.1986.tb04485.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chesa P. G., Rettig W. J., Melamed M. R., Old L. J., Niman H. L. Expression of p21ras in normal and malignant human tissues: lack of association with proliferation and malignancy. Proc Natl Acad Sci U S A. 1987 May;84(10):3234–3238. doi: 10.1073/pnas.84.10.3234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ciardiello F., McGeady M. L., Kim N., Basolo F., Hynes N., Langton B. C., Yokozaki H., Saeki T., Elliott J. W., Masui H. Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation. Cell Growth Differ. 1990 Sep;1(9):407–420. [PubMed] [Google Scholar]
  13. Clair T., Miller W. R., Cho-Chung Y. S. Prognostic significance of the expression of a ras protein with a molecular weight of 21,000 by human breast cancer. Cancer Res. 1987 Oct 15;47(20):5290–5293. [PubMed] [Google Scholar]
  14. DeBortoli M. E., Abou-Issa H., Haley B. E., Cho-Chung Y. S. Amplified expression of p21 ras protein in hormone-dependent mammary carcinomas of humans and rodents. Biochem Biophys Res Commun. 1985 Mar 15;127(2):699–706. doi: 10.1016/s0006-291x(85)80218-7. [DOI] [PubMed] [Google Scholar]
  15. Didsbury J., Weber R. F., Bokoch G. M., Evans T., Snyderman R. rac, a novel ras-related family of proteins that are botulinum toxin substrates. J Biol Chem. 1989 Oct 5;264(28):16378–16382. [PubMed] [Google Scholar]
  16. Downward J., Graves J. D., Warne P. H., Rayter S., Cantrell D. A. Stimulation of p21ras upon T-cell activation. Nature. 1990 Aug 23;346(6286):719–723. doi: 10.1038/346719a0. [DOI] [PubMed] [Google Scholar]
  17. Evans T., Hart M. J., Cerione R. A. The Ras superfamilies: regulatory proteins and post-translational modifications. Curr Opin Cell Biol. 1991 Apr;3(2):185–191. doi: 10.1016/0955-0674(91)90137-n. [DOI] [PubMed] [Google Scholar]
  18. Feramisco J. R., Gross M., Kamata T., Rosenberg M., Sweet R. W. Microinjection of the oncogene form of the human H-ras (T-24) protein results in rapid proliferation of quiescent cells. Cell. 1984 Aug;38(1):109–117. doi: 10.1016/0092-8674(84)90531-2. [DOI] [PubMed] [Google Scholar]
  19. Field J. K., Spandidos D. A. The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis (review). Anticancer Res. 1990 Jan-Feb;10(1):1–22. [PubMed] [Google Scholar]
  20. Franza B. R., Jr, Maruyama K., Garrels J. I., Ruley H. E. In vitro establishment is not a sufficient prerequisite for transformation by activated ras oncogenes. Cell. 1986 Feb 14;44(3):409–418. doi: 10.1016/0092-8674(86)90462-9. [DOI] [PubMed] [Google Scholar]
  21. Fromowitz F. B., Viola M. V., Chao S., Oravez S., Mishriki Y., Finkel G., Grimson R., Lundy J. ras p21 expression in the progression of breast cancer. Hum Pathol. 1987 Dec;18(12):1268–1275. doi: 10.1016/s0046-8177(87)80412-4. [DOI] [PubMed] [Google Scholar]
  22. Furth M. E., Aldrich T. H., Cordon-Cardo C. Expression of ras proto-oncogene proteins in normal human tissues. Oncogene. 1987 Mar;1(1):47–58. [PubMed] [Google Scholar]
  23. Furth M. E., Davis L. J., Fleurdelys B., Scolnick E. M. Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family. J Virol. 1982 Jul;43(1):294–304. doi: 10.1128/jvi.43.1.294-304.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Gallick G. E., Kurzrock R., Kloetzer W. S., Arlinghaus R. B., Gutterman J. U. Expression of p21ras in fresh primary and metastatic human colorectal tumors. Proc Natl Acad Sci U S A. 1985 Mar;82(6):1795–1799. doi: 10.1073/pnas.82.6.1795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ghosh A. K., Moore M., Harris M. Immunohistochemical detection of ras oncogene p21 product in benign and malignant mammary tissue in man. J Clin Pathol. 1986 Apr;39(4):428–434. doi: 10.1136/jcp.39.4.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Going J. J., Anderson T. J., Battersby S., MacIntyre C. C. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol. 1988 Jan;130(1):193–204. [PMC free article] [PubMed] [Google Scholar]
  27. Going J. J., Williams A. R., Wyllie A. H., Anderson T. J., Piris J. Optimal preservation of p21 ras immunoreactivity and morphology in paraffin-embedded tissue. J Pathol. 1988 Jul;155(3):185–190. doi: 10.1002/path.1711550302. [DOI] [PubMed] [Google Scholar]
  28. Gutheil J. C., Mane S., Kapil V., Needleman S. W. Immunoprecipitation of cell lysates with RAP-5 does not specifically detect ras oncogene product p21. Hum Pathol. 1989 Dec;20(12):1176–1180. doi: 10.1016/s0046-8177(89)80008-5. [DOI] [PubMed] [Google Scholar]
  29. Hancock J. F., Magee A. I., Childs J. E., Marshall C. J. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell. 1989 Jun 30;57(7):1167–1177. doi: 10.1016/0092-8674(89)90054-8. [DOI] [PubMed] [Google Scholar]
  30. Hawkins R. A., Black R., Steele R. J., Dixon J. M., Forrest A. P. Oestrogen receptor concentration in primary breast cancer and axillary node metastases. Breast Cancer Res Treat. 1981;1(3):245–251. doi: 10.1007/BF01806264. [DOI] [PubMed] [Google Scholar]
  31. Holgate C. S., Jackson P., Pollard K., Lunny D., Bird C. C. Effect fixation on T and B lymphocyte surface membrane antigen demonstration in paraffin processed tissue. J Pathol. 1986 Aug;149(4):293–300. doi: 10.1002/path.1711490405. [DOI] [PubMed] [Google Scholar]
  32. Joshi K., Smith J. A., Perusinghe N., Monoghan P. Cell proliferation in the human mammary epithelium. Differential contribution by epithelial and myoepithelial cells. Am J Pathol. 1986 Aug;124(2):199–206. [PMC free article] [PubMed] [Google Scholar]
  33. Koutselini H., Kappatou G., Yiagnisis M., Field J. K., Spandidos D. A. Immunocytochemical study of RAS oncoprotein in cytologic specimens of primary lung tumours. Anticancer Res. 1990 May-Jun;10(3):597–603. [PubMed] [Google Scholar]
  34. Lacal J. C., Aaronson S. A. Monoclonal antibody Y13-259 recognizes an epitope of the p21 ras molecule not directly involved in the GTP-binding activity of the protein. Mol Cell Biol. 1986 Apr;6(4):1002–1009. doi: 10.1128/mcb.6.4.1002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Lowe D. G., Capon D. J., Delwart E., Sakaguchi A. Y., Naylor S. L., Goeddel D. V. Structure of the human and murine R-ras genes, novel genes closely related to ras proto-oncogenes. Cell. 1987 Jan 16;48(1):137–146. doi: 10.1016/0092-8674(87)90364-3. [DOI] [PubMed] [Google Scholar]
  36. Mulcahy L. S., Smith M. R., Stacey D. W. Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature. 1985 Jan 17;313(5999):241–243. doi: 10.1038/313241a0. [DOI] [PubMed] [Google Scholar]
  37. Nimmo E. R., Sanders P. G., Padua R. A., Hughes D., Williamson R., Johnson K. J. The MEL gene: a new member of the RAB/YPT class of RAS-related genes. Oncogene. 1991 Aug;6(8):1347–1351. [PubMed] [Google Scholar]
  38. Ohuchi N., Thor A., Page D. L., Hand P. H., Halter S. A., Schlom J. Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues. Cancer Res. 1986 May;46(5):2511–2519. [PubMed] [Google Scholar]
  39. Papadimitriou K., Yiagnisis M., Tolis G., Spandidos D. A. Immunohistochemical analysis of the ras oncogene protein product in human thyroid neoplasms. Anticancer Res. 1988 Nov-Dec;8(6):1223–1227. [PubMed] [Google Scholar]
  40. Pays E., Houard S., Pays A., Van Assel S., Dupont F., Aerts D., Huet-Duvillier G., Gomés V., Richet C., Degand P. Trypanosoma brucei: the extent of conversion in antigen genes may be related to the DNA coding specificity. Cell. 1985 Oct;42(3):821–829. doi: 10.1016/0092-8674(85)90278-8. [DOI] [PubMed] [Google Scholar]
  41. Robinson A., Williams A. R., Piris J., Spandidos D. A., Wyllie A. H. Evaluation of a monoclonal antibody to ras peptide, RAP-5, claimed to bind preferentially to cells of infiltrating carcinomas. Br J Cancer. 1986 Dec;54(6):877–883. doi: 10.1038/bjc.1986.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Rochlitz C. F., Scott G. K., Dodson J. M., Liu E., Dollbaum C., Smith H. S., Benz C. C. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res. 1989 Jan 15;49(2):357–360. [PubMed] [Google Scholar]
  43. Samowitz W. S., Paull G., Hamilton S. R. Reported binding of monoclonal antibody RAP-5 to formalin-fixed tissue sections is not indicative of ras p21 expression. Hum Pathol. 1988 Feb;19(2):127–132. doi: 10.1016/s0046-8177(88)80339-3. [DOI] [PubMed] [Google Scholar]
  44. Sigal I. S., Gibbs J. B., D'Alonzo J. S., Scolnick E. M. Identification of effector residues and a neutralizing epitope of Ha-ras-encoded p21. Proc Natl Acad Sci U S A. 1986 Jul;83(13):4725–4729. doi: 10.1073/pnas.83.13.4725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Spandidos D. A., Agnantis N. J. Human malignant tumours of the breast, as compared to their respective normal tissue, have elevated expression of the Harvey ras oncogene. Anticancer Res. 1984 Jul-Oct;4(4-5):269–272. [PubMed] [Google Scholar]
  46. Spandidos D. A., Dimitrov T. High expression levels of ras p21 protein in normal mouse heart tissues. Biosci Rep. 1985 Dec;5(12):1035–1039. doi: 10.1007/BF01119624. [DOI] [PubMed] [Google Scholar]
  47. Srivastava S. K., Di Donato A., Lacal J. C. H-ras mutants lacking the epitope for the neutralizing monoclonal antibody Y13-259 show decreased biological activity and are deficient in GTPase-activating protein interaction. Mol Cell Biol. 1989 Apr;9(4):1779–1783. doi: 10.1128/mcb.9.4.1779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Strange R., Aguilar-Cordova E., Young L. J., Billy H. T., Dandekar S., Cardiff R. D. Harvey-ras mediated neoplastic development in the mouse mammary gland. Oncogene. 1989 Mar;4(3):309–315. [PubMed] [Google Scholar]
  49. Telang N. T., Basu A., Modak M. J., Osborne M. P. Cellular ras protooncogene expression in human mammary explant cultures. A potential marker for chemical carcinogenesis. Ann N Y Acad Sci. 1990;586:230–237. doi: 10.1111/j.1749-6632.1990.tb17811.x. [DOI] [PubMed] [Google Scholar]
  50. Tiniakos D., Spandidos D. A., Kakkanas A., Pintzas A., Pollice L., Tiniakos G. Expression of ras and myc oncogenes in human hepatocellular carcinoma and non-neoplastic liver tissues. Anticancer Res. 1989 May-Jun;9(3):715–721. [PubMed] [Google Scholar]
  51. Vogelstein B., Fearon E. R., Hamilton S. R., Kern S. E., Preisinger A. C., Leppert M., Nakamura Y., White R., Smits A. M., Bos J. L. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988 Sep 1;319(9):525–532. doi: 10.1056/NEJM198809013190901. [DOI] [PubMed] [Google Scholar]
  52. Walker R. A., Wilkinson N. p21 ras protein expression in benign and malignant human breast. J Pathol. 1988 Oct;156(2):147–153. doi: 10.1002/path.1711560209. [DOI] [PubMed] [Google Scholar]
  53. Ward J. M., Perantoni A. O., Santos E. Comparative immunohistochemical reactivity of monoclonal and polyclonal antibodies to H-ras p21 in normal and neoplastic tissues of rodents and humans. Oncogene. 1989 Feb;4(2):203–213. [PubMed] [Google Scholar]
  54. Wellings S. R., Jensen H. M. On the origin and progression of ductal carcinoma in the human breast. J Natl Cancer Inst. 1973 May;50(5):1111–1118. doi: 10.1093/jnci/50.5.1111. [DOI] [PubMed] [Google Scholar]
  55. Williams A. R., Piris J., Spandidos D. A., Wyllie A. H. Immunohistochemical detection of the ras oncogene p21 product in an experimental tumour and in human colorectal neoplasms. Br J Cancer. 1985 Nov;52(5):687–693. doi: 10.1038/bjc.1985.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Willingham M. C., Pastan I., Shih T. Y., Scolnick E. M. Localization of the src gene product of the Harvey strain of MSV to plasma membrane of transformed cells by electron microscopic immunocytochemistry. Cell. 1980 Apr;19(4):1005–1014. doi: 10.1016/0092-8674(80)90091-4. [DOI] [PubMed] [Google Scholar]
  57. Willumsen B. M., Christensen A., Hubbert N. L., Papageorge A. G., Lowy D. R. The p21 ras C-terminus is required for transformation and membrane association. Nature. 1984 Aug 16;310(5978):583–586. doi: 10.1038/310583a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES